Peptides for Weight Loss: What Works, What's Hype, and How to Keep Your Muscle
A doctor-reviewed guide to the peptides marketed for weight loss — which ones the science actually backs, which are mostly hype, and how to make sure the weight you lose is fat, not muscle.
The short answer
"Peptides for weight loss" covers two very different groups. The GLP-1 class of peptide medications — semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda) — are FDA-approved, backed by large clinical trials, and produce 8% to 22% average body-weight loss. A second group of "research peptides" (AOD-9604, CJC-1295, ipamorelin, tesamorelin, 5-Amino-1MQ) is heavily marketed for fat loss but has limited or preclinical human evidence and no FDA approval for weight loss.
The catch nobody tells you: rapid weight loss on any peptide burns muscle alongside fat — up to 40% of the weight lost in trials was lean mass. The only way to know which you're losing is to measure it.
Key takeaways
- The peptides with real, FDA-approved weight-loss evidence are all GLP-1-based: semaglutide, tirzepatide, and liraglutide.
- Tirzepatide has produced the largest average loss in trials (up to 22.5%), followed by semaglutide (~15%) and liraglutide (~8%).
- Growth-hormone "research peptides" like CJC-1295, ipamorelin, and AOD-9604 are not FDA-approved for weight loss and lack robust human trial data.
- 25–40% of the weight lost on a GLP-1 can be lean muscle mass — a real risk to your metabolism that most guides ignore.
- A DEXA scan is the accessible, objective way to confirm you're losing fat and not muscle.
- Only use peptides prescribed and supervised by a licensed clinician — not "research-only" products sold online.
What Are Peptides for Weight Loss?
Peptides are short chains of amino acids — the same building blocks that make up proteins, just smaller. Your body uses many of them as signaling molecules: hormones and messengers that tell cells what to do. Insulin is a peptide. So is the hormone GLP-1 that your gut releases after a meal to tell your brain you're full.
In weight-loss marketing, "peptide" gets used loosely for two groups that are worlds apart in evidence:
- GLP-1 peptide medications — semaglutide, tirzepatide, and liraglutide. These are FDA-approved prescription drugs, studied in trials with thousands of participants, and they are what most people are actually losing weight on.
- "Research" or "growth-hormone" peptides — AOD-9604, CJC-1295, ipamorelin, tesamorelin, 5-Amino-1MQ, MOTS-c, and others. These are sold by some wellness clinics and online vendors on the promise of fat loss, but the human evidence ranges from thin to nonexistent, and none are FDA-approved for weight loss.
The distinction matters because the two groups don't produce remotely similar results — and being clear about which is which is the difference between an evidence-based decision and an expensive experiment.
How Peptides Cause Weight Loss
The GLP-1 medications work by mimicking gut hormones your body already makes after eating. They act on receptors in the brain and digestive tract to:
- Reduce appetite and hunger by acting on the brain's satiety centers, so you feel full sooner and stay full longer.
- Slow gastric emptying, keeping food in your stomach longer and blunting post-meal blood-sugar spikes.
- Improve insulin response, which is why several of these drugs were first approved for type 2 diabetes.
The newer drugs stack additional hormone targets on top of GLP-1. Tirzepatide also activates the GIP receptor (a "dual agonist"), and the investigational retatrutide adds a third target, the glucagon receptor (a "triple agonist"), which appears to further increase energy expenditure. More targets have generally meant more weight loss in trials.
The growth-hormone peptides work on a completely different pathway — they try to stimulate the body's own growth-hormone release, which in theory promotes fat breakdown (lipolysis). The theory is plausible; the human weight-loss evidence is what's missing.
Peptides for Weight Loss Compared
Here is every peptide commonly marketed for weight loss, grouped by how strong the evidence actually is. Weight-loss figures are average results from the named clinical trial at the highest studied dose.
| Peptide | Class | FDA status (weight loss) | Evidence | How it's taken |
|---|---|---|---|---|
| Semaglutide Wegovy, Ozempic* FDA-approved | GLP-1 receptor agonist | FDA-approved for weight management (Wegovy) | ≈15% mean body-weight loss at 68 weeks (STEP 1, NEJM 2021) | Weekly subcutaneous injection |
| Tirzepatide Zepbound, Mounjaro* FDA-approved | Dual GIP/GLP-1 receptor agonist | FDA-approved for weight management (Zepbound) | Up to 22.5% mean body-weight loss at 72 weeks (SURMOUNT-1, NEJM 2022) | Weekly subcutaneous injection |
| Liraglutide Saxenda, Victoza* FDA-approved | GLP-1 receptor agonist | FDA-approved for weight management (Saxenda) | ≈8% mean body-weight loss at 56 weeks (SCALE, NEJM 2015) | Daily subcutaneous injection |
| Retatrutide (investigational) In trials | Triple GIP/GLP-1/glucagon agonist | Not approved — in phase 3 trials | Up to 24.2% mean body-weight loss at 48 weeks (phase 2, NEJM 2023) | Weekly subcutaneous injection |
| Tesamorelin Egrifta Limited evidence | Growth-hormone-releasing hormone (GHRH) analog | FDA-approved only for HIV-associated visceral fat; off-label otherwise | Reduces visceral fat in HIV lipodystrophy; general-population weight-loss data limited | Daily subcutaneous injection |
| AOD-9604 (research peptide) Limited evidence | Modified fragment of human growth hormone | Not FDA-approved for weight loss | ≈2.6 kg vs 0.8 kg placebo over 12 weeks in one trial — modest, not robust | Subcutaneous injection or oral |
| CJC-1295 / Ipamorelin (research peptides) Limited evidence | Growth-hormone secretagogues | Not FDA-approved for weight loss | Raise GH/IGF-1 in trials; no robust human weight-loss outcome data | Subcutaneous injection |
| 5-Amino-1MQ (research compound) Limited evidence | NNMT enzyme inhibitor | Not FDA-approved; no completed human weight-loss trials | Preclinical (animal/cell) fat-loss signals only | Oral capsule |
| MOTS-c (research peptide) Limited evidence | Mitochondrial-derived peptide | Not FDA-approved; no completed human weight-loss trials | Preclinical metabolic signals only | Subcutaneous injection |
Ozempic, Mounjaro, and Victoza are the type-2-diabetes brand names; Wegovy, Zepbound, and Saxenda are the same molecules approved specifically for weight management. Trial sources are cited in the sections below.
The Peptides That Actually Work (FDA-Approved GLP-1s)
Semaglutide (Wegovy, Ozempic)
The most widely used weight-loss peptide. In the landmark STEP 1 trial (1,961 adults, published in the New England Journal of Medicine in 2021), once-weekly semaglutide 2.4 mg produced an average 14.9% reduction in body weight over 68 weeks, versus 2.4% on placebo. About 86% of participants lost at least 5% of their body weight, and half lost 15% or more. Sold as Wegovy for weight loss and Ozempic for type 2 diabetes (same molecule, different labeling).
Tirzepatide (Zepbound, Mounjaro)
A dual GIP/GLP-1 agonist and the current efficacy leader. In SURMOUNT-1 (NEJM, 2022), once-weekly tirzepatide produced average weight loss of 16% (5 mg), 21.4% (10 mg), and 22.5% (15 mg) over 72 weeks. On the top dose, most participants lost at least 20% of their body weight. Sold as Zepbound for weight loss and Mounjaro for diabetes; Zepbound is also FDA-approved for moderate-to-severe obstructive sleep apnea.
Liraglutide (Saxenda, Victoza)
The original GLP-1 approved for weight management (2014). It's a daily rather than weekly injection, and its results are more modest: the SCALE trial (NEJM, 2015) found an average 8% body-weight loss at 56 weeks on the 3.0 mg dose. Largely superseded by the weekly drugs, but still used and, as an older molecule, sometimes more accessible.
Losing weight on a GLP-1 or peptide? Make sure it's fat, not muscle. In clinical trials, roughly a quarter to 40% of the weight lost on GLP-1 medications was lean mass, not fat. A DEXA scan measures your body fat, lean muscle, and visceral fat directly — the objective baseline-and-follow-up the scale can't give you. Scans start at $99, take about 10 minutes, and need no referral.
Find a DEXA Scan Near You →⭐ The Muscle-Loss Problem Nobody Tells You About
Here's what most peptide articles leave out: a large share of the weight you lose on a GLP-1 is muscle, not fat. When you lose weight rapidly — from any cause — your body sheds lean tissue alongside fat.
In the STEP 1 body-composition sub-study, which used DEXA scans to measure exactly what was lost, roughly 40% of the total weight participants lost on semaglutide was lean mass (muscle and other non-fat tissue), with about 60% coming from fat. Tirzepatide trials show a similar pattern. That's better than the muscle loss seen with crash dieting, but it is far from trivial — and it has real consequences.
Why it matters:
- Muscle drives your metabolism. Lose too much of it and your resting calorie burn drops, making weight easier to regain.
- Regain hits fat first. When people stop a GLP-1, studies show most of the weight comes back — and it returns as fat, not the muscle they lost. You can end up with a worse body composition than you started with.
- Strength and function. For older adults especially, losing muscle mass raises the risk of frailty and falls.
How to protect your muscle while on a peptide:
- Eat enough protein — many clinicians target roughly 1.2–1.6 grams per kilogram of body weight per day during active weight loss (confirm with your own provider).
- Do resistance training 2–3 times a week. This is the single most effective way to preserve lean mass while losing fat.
- Measure, don't guess. The scale can't tell muscle from fat. A DEXA scan separates the two, so you can catch excessive muscle loss early and adjust.
This is why a baseline DEXA scan before you start, and a follow-up every 8–12 weeks, is the smartest thing you can do on a GLP-1 — it turns "the scale is moving" into "I'm losing fat and keeping muscle."
What's Coming Next: The Peptide Pipeline
Several next-generation peptides are in late-stage trials and may raise the ceiling further:
- Retatrutide — a "triple agonist" (GLP-1, GIP, and glucagon) from Eli Lilly. In a phase 2 trial (NEJM, 2023), it produced up to 24.2% average weight loss at 48 weeks, the highest reported for any drug in this class so far. Now in phase 3.
- Survodutide — a GLP-1/glucagon dual agonist in trials for obesity and liver disease (MASH), with roughly 19% weight loss reported in phase 2.
- Oral and higher-dose options — an oral semaglutide tablet for weight loss and higher-dose (7.2 mg) semaglutide have both reported strong results in 2025 trials, and other oral agents are in development, which could reduce reliance on injections.
None of these is a shortcut available today — they're investigational, meaning not yet FDA-approved. But they signal where the field is heading: more weight loss, and eventually pills instead of shots.
"Research Peptides": What the Evidence Actually Shows
These are the peptides you'll see advertised by wellness clinics and online vendors. We've graded each one honestly. None is FDA-approved for weight loss, and in 2023 the FDA placed several on a restricted list for compounding, citing concerns about immune reactions, impurities, and limited safety data (the regulatory status has been contested and continues to shift). Treat anything in this group as unproven for weight loss.
Tesamorelin (Egrifta)
FDA-approved, but only to reduce excess visceral (belly) fat in people with HIV-associated lipodystrophy. It genuinely reduces visceral fat in that population, which is why it's used off-label elsewhere — but general-population weight-loss evidence is limited. A daily injection.
AOD-9604
A fragment of human growth hormone. One 12-week trial in adults with obesity found it produced only about 2.6 kg of weight loss versus 0.8 kg on placebo — a modest effect, and not replicated at scale. Not FDA-approved for weight loss.
CJC-1295 & Ipamorelin
Growth-hormone secretagogues, often sold as a stack. Trials confirm they raise growth hormone and IGF-1 levels, but there is no robust human evidence that this translates into meaningful weight or fat loss. Not FDA-approved; both are on the FDA's restricted compounding list.
5-Amino-1MQ & MOTS-c
Newer metabolic compounds with interesting fat-loss signals in animal and cell studies, but no completed human weight-loss trials. Marketing far outpaces the evidence. Not FDA-approved.
BPC-157, TB-500, Sermorelin
Frequently marketed alongside weight-loss peptides, but these target tissue repair, recovery, or growth-hormone release — not weight loss specifically. Human evidence for a weight-loss benefit is essentially absent, and several are on the FDA's restricted list.
Bottom line: if a clinic promises Ozempic-like results from a growth-hormone peptide, the trial data don't support that claim. These compounds may have legitimate research interest, but "marketed for fat loss" is not the same as "proven to cause fat loss."
Side Effects & Who Should Avoid Them
The most common side effects of the GLP-1 peptides are gastrointestinal: nausea, diarrhea, constipation, and vomiting, especially when starting or increasing the dose. These usually ease over time and are managed with gradual dose titration.
More serious but less common risks include pancreatitis, gallbladder problems, and kidney injury from dehydration. These drugs carry a boxed warning about a risk of thyroid C-cell tumors seen in rodents, and they are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. They are not for use in pregnancy.
The larger safety concern with unapproved research peptides is what you're actually injecting: products from unregulated "research-only" sources may not contain what the label claims, may be contaminated, and have not been through the safety testing that approved drugs undergo. This is a core reason to work only with a licensed prescriber and pharmacy.
Cost & How to Get Them Legally
Brand-name GLP-1 medications list at roughly $1,000–$1,350 per month before insurance or manufacturer savings programs. Coverage varies widely — some plans cover them for obesity, many only for diabetes, and out-of-pocket cost is the biggest practical barrier for most people. Manufacturer savings cards can substantially reduce the price for eligible patients.
Compounded semaglutide and tirzepatide have been offered for less (roughly $150–$500/month) through some telehealth services and compounding pharmacies, but the availability and legality of compounding shift with FDA drug-shortage and enforcement decisions — so verify the current status with a licensed provider rather than assuming.
The safe, legal route is a prescription from a licensed clinician — your primary-care doctor, an obesity-medicine specialist, or a reputable telehealth service — dispensed by a licensed pharmacy. Avoid anything sold as "research-only" or "not for human consumption"; those products are unregulated and their purity and dosing are unverified.
How to Know If It's Actually Working
The bathroom scale is the worst tool for this job. It shows total weight, but it can't tell you whether you're losing fat (good) or muscle (bad), and it swings with water and food. On a peptide, where protecting muscle is the whole game, you need to see inside the number.
A DEXA scan is the clinical gold standard for body composition. In a single 10-minute scan it measures:
- Body fat percentage and total fat mass — so you can confirm fat is actually coming off.
- Lean muscle mass, by body region — so you catch muscle loss early enough to correct it.
- Visceral fat — the metabolically dangerous fat around your organs, which GLP-1s reduce.
The ideal approach: a baseline scan before you start, then a follow-up every 8–12 weeks. That cadence is long enough to show real change and tight enough to adjust your protein and training if you're losing too much muscle. It turns your peptide from a leap of faith into a measured, managed process.
Starting a GLP-1? Get a baseline DEXA scan first. In clinical trials, roughly a quarter to 40% of the weight lost on GLP-1 medications was lean mass, not fat. A DEXA scan measures your body fat, lean muscle, and visceral fat directly — the objective baseline-and-follow-up the scale can't give you. Scans start at $99, take about 10 minutes, and need no referral.
Find a DEXA Scan Near You →Peptides for Weight Loss: FAQ
What are peptides for weight loss?
Peptides are short chains of amino acids that act as signaling molecules in the body. For weight loss, the term covers two very different groups. The first is the GLP-1 class of peptide medications — semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda) — which are FDA-approved, backed by large clinical trials, and produce 8–22% average body-weight loss. The second is a group of "research peptides" such as AOD-9604, CJC-1295, ipamorelin, tesamorelin, and 5-Amino-1MQ, which are marketed for fat loss but have limited or preclinical human evidence and are not FDA-approved for weight loss.
Do peptides actually work for weight loss?
The GLP-1 peptide medications work, and the evidence is strong: in randomized trials, semaglutide produced about 15% average body-weight loss over 68 weeks and tirzepatide up to 22.5% over 72 weeks. The "research peptides" (AOD-9604, CJC-1295/ipamorelin, 5-Amino-1MQ, MOTS-c) are a different story — human weight-loss evidence is weak, preclinical, or absent, and none are FDA-approved for weight loss. If a clinic promises Ozempic-like results from a growth-hormone peptide, the trial data don't support that claim.
What is the best peptide for weight loss?
For most people, tirzepatide (Zepbound) has produced the largest average weight loss in head-to-head-caliber trial data — up to 22.5% — followed by semaglutide (Wegovy) at about 15%. Both are FDA-approved GLP-1-class peptides taken as a weekly injection. "Best" also depends on your medical history, insurance, side-effect tolerance, and whether you can protect muscle mass — which is why these medications should be prescribed and monitored by a clinician, ideally with body-composition testing.
Do peptides for weight loss cause muscle loss?
Yes — this is the most overlooked risk. In the STEP 1 body-composition sub-study, about 40% of the total weight people lost on semaglutide was lean mass (muscle and other non-fat tissue), not fat. Rapid weight loss of any kind burns muscle alongside fat. You can blunt this with adequate protein intake and resistance training, and you can measure it directly with a DEXA scan, which separates fat mass from lean mass so you know whether you're losing the right kind of weight.
Are peptides for weight loss safe?
The FDA-approved GLP-1 peptides have a well-characterized safety profile — the most common side effects are gastrointestinal (nausea, diarrhea, constipation), and there are specific warnings and contraindications your prescriber will review. The bigger safety question surrounds unapproved research peptides sold online or through some compounding channels: the FDA has flagged several for immunogenicity risk, impurities, and limited safety data, and products from unregulated sources may not contain what the label claims. Only use peptides prescribed and supervised by a licensed clinician.
How much do peptides for weight loss cost?
Brand-name GLP-1 medications list around $1,000–$1,350 per month before insurance or manufacturer savings programs; coverage varies widely by plan and indication. Compounded semaglutide or tirzepatide has been offered for less (roughly $150–$500/month) through telehealth and compounding pharmacies, but availability and legality shift with FDA supply and enforcement decisions, so verify current status with a licensed provider. Research peptides are often cheaper still, but you're paying for products without proven weight-loss benefit.
Where can I get peptides for weight loss?
The safe, legal route is a prescription from a licensed clinician — a primary-care doctor, an obesity-medicine specialist, or a reputable telehealth service — dispensed by a licensed pharmacy. Avoid "research-only" peptides sold online with a not-for-human-use disclaimer; those are unregulated and their purity and dosing are unverified. Before and during treatment, a DEXA scan gives you an objective baseline and shows whether you're losing fat rather than muscle.
Are peptide injections better than oral peptides for weight loss?
Most peptides with real evidence are injectable, because peptides are broken down in the digestive tract and absorb poorly by mouth. Semaglutide, tirzepatide, and liraglutide are all injections (an oral semaglutide tablet exists but at different dosing). "Oral peptides for weight loss" marketed as drops or capsules usually either aren't the same molecule as the injectable drug or lack evidence they're absorbed and effective. Route matters less than whether the specific product has trial data behind it.
How do I know if my weight-loss peptide is working?
The scale alone can mislead you, because it can't tell fat loss from muscle loss or water shifts. The objective way to track a weight-loss peptide is a DEXA (dual-energy X-ray absorptiometry) scan every 8–12 weeks: it measures body fat percentage, lean muscle mass by region, and visceral fat, so you can confirm the weight coming off is fat and catch excessive muscle loss early enough to correct it with protein and resistance training.
The Bottom Line
If you want peptides for weight loss and you want results the science supports, that means the GLP-1 class — semaglutide, tirzepatide, or liraglutide — prescribed and monitored by a licensed clinician. The growth-hormone "research peptides" are, for now, marketing ahead of evidence.
And whichever route you take, remember the part the ads skip: the goal isn't just a smaller number on the scale, it's losing fat while keeping your muscle. Eat enough protein, lift weights, and measure your body composition with a DEXA scan so you actually know what's happening — not just that you weigh less.
Medical Disclaimer: The information provided on this website is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. DEXA scan results should be interpreted by a qualified healthcare professional.